WEREWOLF THERAPEUTICS INC (HOWL) Stock Price, Forecast & Analysis
USA - NASDAQ:HOWL - US95075A1079 - Common Stock
HOWL Key Statistics, Chart & Performance
The current stock price of HOWL is 0.9194 USD. In the past month the price decreased by -43.25%. In the past year, price decreased by -51.61%.
HOWL Latest News, Press Relases and Analysis
HOWL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About HOWL
Company Profile
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Company Info
WEREWOLF THERAPEUTICS INC
200 Talcott Avenue, 2nd Floor
Watertown MASSACHUSETTS 02138 US
CEO: Daniel J. Hicklin
Employees: 46
Phone: 16179520555
WEREWOLF THERAPEUTICS INC / HOWL FAQ
What does WEREWOLF THERAPEUTICS INC do?
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
What is the current price of HOWL stock?
The current stock price of HOWL is 0.9194 USD. The price increased by 0.13% in the last trading session.
What is the dividend status of WEREWOLF THERAPEUTICS INC?
HOWL does not pay a dividend.
What is the ChartMill technical and fundamental rating of HOWL stock?
HOWL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of WEREWOLF THERAPEUTICS INC (HOWL)?
WEREWOLF THERAPEUTICS INC (HOWL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
Is WEREWOLF THERAPEUTICS INC (HOWL) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HOWL.
What is the next earnings date for HOWL stock?
WEREWOLF THERAPEUTICS INC (HOWL) will report earnings on 2026-03-02, after the market close.
HOWL Technical Analysis
HOWL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOWL. HOWL has a bad profitability rating. Also its financial health evaluation is rather negative.
HOWL Financial Highlights
Over the last trailing twelve months HOWL reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS decreased by -8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.48% | ||
| ROE | -245.97% | ||
| Debt/Equity | 0.73 |
HOWL Forecast & Estimates
12 analysts have analysed HOWL and the average price target is 6.97 USD. This implies a price increase of 658.1% is expected in the next year compared to the current price of 0.9194.
For the next year, analysts expect an EPS growth of 2.38% and a revenue growth -100% for HOWL